We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Phibro (PAHC) Reports Q4 Earnings: What Key Metrics Have to Say
Read MoreHide Full Article
For the quarter ended June 2026, Phibro Animal Health (PAHC - Free Report) reported revenue of $396.7 million, up 4.8% over the same period last year. EPS came in at $0.85, compared to $0.57 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $366.14 million, representing a surprise of +8.35%. The company delivered an EPS surprise of +18.06%, with the consensus EPS estimate being $0.72.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Phibro performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Net Sales by Region- United States: $220.25 million compared to the $203.34 million average estimate based on two analysts. The reported number represents a change of +9% year over year.
Net Sales by Region- Asia Pacific: $32.52 million versus the two-analyst average estimate of $31.72 million. The reported number represents a year-over-year change of -7.2%.
Net Sales by Region- Europe, Middle East and Africa: $53.75 million versus $53.7 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -6.7% change.
Net Sales by Region- Latin America and Canada: $90.22 million compared to the $71.4 million average estimate based on two analysts. The reported number represents a change of +7.3% year over year.
Net Sales- Animal Health: $297.6 million versus $283.35 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +1.8% change.
Net Sales- Mineral Nutrition: $77 million versus $64.77 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +20% change.
Net Sales- Animal Health- Vaccines: $40.1 million compared to the $38.82 million average estimate based on three analysts. The reported number represents a change of +4% year over year.
Net Sales- Animal Health- MFAs and other: $207.6 million versus the three-analyst average estimate of $196.75 million. The reported number represents a year-over-year change of +0.5%.
Net Sales- Animal Health- Nutritional specialties: $49.9 million compared to the $47.79 million average estimate based on three analysts. The reported number represents a change of +5.3% year over year.
Net Sales- Performance Products: $22.2 million versus the three-analyst average estimate of $18.02 million. The reported number represents a year-over-year change of +0.6%.
Adjusted EBITDA- Animal Health: $75.4 million versus the two-analyst average estimate of $61.41 million.
Adjusted EBITDA- Corporate: $-20.2 million versus $-11.36 million estimated by two analysts on average.
Shares of Phibro have returned -1.2% over the past month versus the Zacks S&P 500 composite's +3.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
View the Zacks #1 Rank List
Image: Bigstock
Phibro (PAHC) Reports Q4 Earnings: What Key Metrics Have to Say
For the quarter ended June 2026, Phibro Animal Health (PAHC - Free Report) reported revenue of $396.7 million, up 4.8% over the same period last year. EPS came in at $0.85, compared to $0.57 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $366.14 million, representing a surprise of +8.35%. The company delivered an EPS surprise of +18.06%, with the consensus EPS estimate being $0.72.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Phibro performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:View all Key Company Metrics for Phibro here>>>
Shares of Phibro have returned -1.2% over the past month versus the Zacks S&P 500 composite's +3.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.